Company Profile

Humacyte Inc
Profile last edited on: 6/9/2024      CAGE: 47PM8      UEI: XRKCWCMCZKE7

Business Identifier: Human tissue-based products for regenerative medicine and vascular surgery
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2525 East North Carolina Highway 54
Morrisville, NC 27713
   (919) 313-9633
Location: Single
Congr. District: 01
County: Wake

Public Profile

Humacyte, Inc., is a medical research, discovery and development company with clinical and pre-clinical stage investigational products primarily focused on developing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery: engineered human collagen-based products The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis. The company's proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 2 NIH $4,373,870
Project Title: Novel Manufacturing Processes for Tissue Engineered Vascular Grafts
2014 1 NIH $217,277
Project Title: Thromboresistant Small Diameter Tissue-Engineered Vascular Grafts

Key People / Management

  Carrie S Cox -- CEO

  Juliana L Blum -- Co-Founder and Vice-President, Business Operations & Tissue Services

  Paul Boyer -- Chief Financial Officer

  Shannon L M Dahl -- Vice-President, Scientific Operations & Co-Founderand Co-founder

  Robert David Kirkton

  Theodore D Lithgow -- Chief Operating Officer

  Laura A Niklason -- Founder & Chief Technical Officer

  Alison Pilgrim -- Chief Medical Officer

  Heather Prichard -- Director of Early Clinical Development

  William E Tente -- Vice-President, Manufacturing And Regulatory Affairs